Skip to main content
. 2020 Oct 5;2020:8823785. doi: 10.1155/2020/8823785

Figure 9.

Figure 9

Bmi1, FoxO1, SOD1, and SOD2 expressions in SGNs after PTC-209 treatment. Distributions and expressions of Bmi1, FoxO1, SOD1, and SOD2 protein in SGNs were detected with the immune-fluorescence assay in the control group and the PTC-209 treated groups (a–d), while the quantity of these protein expressions was analyzed by fluorescence intensity (a′–d′). After PTC-209 treatment, Bmi1/FoxO1/SOD1/SOD2 (red) and tubulin (green) as SGN marker were, respectively, labeled with fluorescent secondary antibody and nuclei (blue) were labeled with DAPI. Scale bars represent 100 μm and 50 μm. Furthermore, values are means ± SD (N = 40 animals from 2 groups). ∗P < 0.05 vs. control group. Statistical analysis of the results presented in (a′–d′) was performed with Student's t-test (∗P < 0.05; N = 40 animals from 2 groups). After PTC-209 treatment, protein expressions of Hsp70, Bmi1, FoxO1, SOD1, and SOD2 were assessed with western blot (e), while the quantity of these protein expressions was analyzed by integrated light density (e′). β-Actin protein was available as an endogenous control. Furthermore, values are means ± SD. ∗P < 0.05 vs. control group. Statistical analysis of the results was performed with two-way ANOVA (interaction: F(4, 20) = 283.78; P < 0.0001; row factor: F(4, 20) = 1276.15; P < 0.0001; column factor: F(1, 20) = 7931.17; P < 0.0001), followed by Student's t-test (∗P < 0.05; n = 12 animals/group).